35
edits
Changes
no edit summary
|Positive (universal)||cyTCL1(highest specificity), CD2, CD3 (may be weak), CD5, CD7 (strong), TCR-α/β
|Positive (universal)||cyTCL1(highest specificity), CD2, CD3 (may be weak), CD5, CD7 (strong), TCR-α/β
|-
|-
|Positive (subset)||CD4 (in some cases CD4+/CD8+ or CD4-/CD8+), CD52, activation markers are variable (CD25, CD38, CD43, CD26, CD27)
|Positive (subset)||CD4 (in some cases CD4+/CD8+ or CD4-/CD8+), CD52, activation markers are variable (CD25, CD38, CD43, CD26, CD27)
|-
|-
|Negative (universal)||TdT, CD1a, CD57, CD16
|Negative (universal)||TdT, CD1a, CD57, CD16
|
|
|-
|-
|''TCL1A''
|ATM
|Oncogene
|TSG
|
|
|ATM mutations
|ATM mutations
|
|
|-
|-
|''JAK1, JAK3, STAT5b, IL2RG''
|''JAK1, JAK3, STAT5B''
|Oncogene
|
|
|
|
|
|
|
|-
|-
|''STAT5B''
|''IL2RG''
|
|
|
|
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|-
|TCL1A
|''TCL1A rearrangement''
|AKT signaling and TCR signal amplification pathways
|''AKT'' signaling and TCR signal amplification pathways
|Increased cell survival and proliferation
|-
|''MTCP1''
|''AKT'' signaling and TCR signal amplification pathways
|Increased cell survival and proliferation
|Increased cell survival and proliferation
|-
|-
|''JAK1, JAK3, STAT5b, IL2RG''
|''ATM, CHEK2''
|JAk-STAT pathway
|DNA damage repair pathway
|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program
|Genomic instability
|-
|''JAK1, JAK3, STAT5B''
|''JAK-STAT'' pathway
|Unchecked cell growth and survival
|-
|''IL2RG''
|Cytokine signaling
|Promoting lymphocyte proliferation
|-
|''EZH2''
|Transcription regulator
|Altering the epigenetic landscape
|}
|}
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==